Background-Phosphoinositide 3-kinase ␥ (PI3K␥) signaling engaged by ␤-adrenergic receptors is pivotal in the regulation of myocardial contractility and remodeling. However, the role of PI3K␥ in catecholamine-induced arrhythmia is currently unknown. Methods and Results-Mice lacking PI3K␥ (PI3K␥ Ϫ/Ϫ ) showed runs of premature ventricular contractions on adrenergic stimulation that could be rescued by a selective ␤ 2 -adrenergic receptor blocker and developed sustained ventricular tachycardia after transverse aortic constriction. Consistently, fluorescence resonance energy transfer probes revealed abnormal cAMP accumulation after ␤ 2 -adrenergic receptor activation in PI3K␥ Ϫ/Ϫ cardiomyocytes that depended on the loss of the scaffold but not of the catalytic activity of PI3K␥. Downstream from ␤-adrenergic receptors, PI3K␥ was found to participate in multiprotein complexes linking protein kinase A to the activation of phosphodiesterase (PDE) 3A, PDE4A, and PDE4B but not of PDE4D. These PI3K␥-regulated PDEs lowered cAMP and limited protein kinase A-mediated phosphorylation of L-type calcium channel (Ca v 1.2) and phospholamban. In PI3K␥ Ϫ/Ϫ cardiomyocytes, Ca v 1.2 and phospholamban were hyperphosphorylated, leading to increased Ca 2ϩ spark occurrence and amplitude on adrenergic stimulation. Furthermore, PI3K␥ Ϫ/Ϫ cardiomyocytes showed spontaneous Ca 2ϩ release events and developed arrhythmic calcium transients. Conclusions-PI3K␥ coordinates the coincident signaling of the major cardiac PDE3 and PDE4 isoforms, thus orchestrating a feedback loop that prevents calcium-dependent ventricular arrhythmia.
ylation of effectors modulating the cardiac excitationcontraction coupling such as the L-type Ca 2ϩ channel (LTCC), the ryanodine receptor (RyR), phospholamban, and troponin I. 4 
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The spatial and temporal compartmentalization of cAMP ensures that PKA encounters its substrates in the right place and at the right time. 5 On agonist stimulation, cAMP does not increase globally. Rather, cAMP is produced in discrete microdomains, thereby initiating defined sets of PKAmediated events. 6 For instance, the 2 main cardiac ␤-AR isoforms, ␤ 1 -AR and ␤ 2 -AR, 7 signal through the common cAMP/PKA pathway, but ␤ 1 -ARs are much more efficient in enhancing cardiac contractility than ␤ 2 -ARs. 8 This is due in part to a differential localization of ␤-AR subtypes, which leads to compartment-restricted cAMP generation. 9, 10 cAMP compartmentalization is also mediated by A-kinase anchoring proteins, which anchor PKA and phosphodiesterases (PDEs) in defined compartments, thus directing localized cAMP destruction. 11, 12 Among cardiac cAMP PDEs, 13 PDE3 and PDE4 provide the main route for cAMP degradation and limit cAMP generated by ␤ 2 -ARs. 14, 15 Disruption of selected and localized subsets of these PDEs has been linked to arrhythmogenesis. In mouse models, defective PDE4D activity in the sarcoplasmic reticulum (SR) RyR complex 2 or defective PDE4B activity in the sarcolemmal LTCC complex 16 leads to catecholamine-induced ventricular arrhythmias. In human patients with heart failure, inhibition of PDE3 by milrinone favors the development of malignant arrhythmias. 17 Phosphoinositide 3-kinase ␥ (PI3K␥) is an emerging regulator of PDE action in the myocardium. In isolated cardiomyocytes, PI3K␥ is required for activation of PDE4 in the vicinity of the SR through an as-yet unknown mechanism. 18 In addition, cardiac PI3K␥ acts as an A-kinase anchoring protein that tethers PDE3B and its activator PKA within the same macromolecular complex to enhance PDE3B activity. 19 Nonetheless, the role of PI3K␥ in arrhythmogenesis is presently unknown.
Here, we report that PI3K␥ protects against catecholamineinduced ventricular arrhythmia by linking ␤ 2 -AR signaling to PKA-mediated activation of the major PDEs controlling cardiac function, PDE4A, PDE4B and PDE3A. The resulting feedback loop limits ␤ 2 -AR-induced cAMP elevation and PKAdependent phosphorylation of LTCC and phospholamban, eventually preventing spontaneous arrhythmogenic Ca 2ϩ release.
Methods
Expanded methods can be found in the Methods section in the online-only Data Supplement.
Mice and Surgical Procedure
PI3K␥-deficient mice (PI3K␥ Ϫ/Ϫ ) and knock-in mice with catalytically inactive PI3K␥ (PI3K␥ KD/KD ) were generated as previously described. 20, 21 Mutant mice were backcrossed with C57Bl/6 mice for 15 generations to inbreed the genetic background, and C57Bl/6 mice (PI3K␥ ϩ/ϩ ) were used as controls. Mechanical stress was imposed on the left ventricle by transverse aortic constriction between the truncus anonymous and the left carotid artery, as previously reported. 21 
ECG Recording
For evaluation of epinephrine-induced arrhythmias, mice were anesthetized with 1% isoflurane and subjected to intraperitoneal injection of the indicated drugs under continuous ECG monitoring with a Vevo 2100 echocardiograph (VisualSonics, Toronto, Canada). In transverse aortic constriction-treated animals, serial ECG monitoring was performed 4 times daily, for a total of 4 hours, starting on day 3 after surgery.
Fluorescence Resonance Energy Transfer Imaging
Spontaneously beating neonatal cardiomyocytes were cultured on fibronectin-coated tissue culture dishes in a Dulbecco modified Eagle medium/Medium 199 (Gibco, Carlsbad, CA) mix containing 10% horse serum, 5% FBS, and 5 mmol/L penicillin/streptomycin. At 12 to 24 hours after plating, cells were infected with an adenovirus encoding Epac2-cAMPs 22 or pm-Epac2-cAMPs, a plasma membranetargeted version of Epac2-cAMPs, 23 and live cell imaging was performed 24-hours after adenovirus infection, as previously described. 24
Ca 2؉ Measurements
For Ca 2ϩ spark measurements, adult ventricular cardiomyocytes were loaded with the Ca 2ϩ fluorescence dye fluo-4AM (Molecular Probes, Invitrogen Corp, Carlsbad, CA), as previously described. 25 Ca 2ϩ sparks were visualized in quiescent cardiomyocytes by a Leica SP5 confocal microscope (Leica Microsystems Inc, Germany) fitted with a white-light laser tuned to 500 nm. For Ca 2ϩ transient measurements, adult ventricular cardiomyocytes were loaded with Fura-2AM (Molecular Probes) and field stimulated at a frequency of 0.5 Hz. The Fura-2 ratios were recorded with an IonOptix System (IonOptix, Milton, MA), as previously detailed. 16 
PDE Assay
PDE activity in immunoprecipitates was measured according to the 2-step method of Thompson and Appleman, 26 as previously described. 27 
Statistical Analysis
Prism software (GraphPad software Inc, La Jolla, CA) was used for statistical analysis. P values were calculated with the Kruskal-Wallis nonparametric test followed by the Dunn post hoc analysis. The Fisher exact test was used to evaluate arrhythmia incidence, and the log-rank test was used for survival analysis.
Results

PI3K␥-Null Mice Are Susceptible to ␤ 2 -AR-Triggered Ventricular Arrhythmia
To evaluate the effect of PI3K␥ on catecholamine-induced arrhythmia, ECGs were recorded in PI3K␥ ϩ/ϩ , PI3K␥ Ϫ/Ϫ , and PI3K␥ KD/KD animals treated with epinephrine (2 mg/kg IP). Basal heart rate was similar in all genotypes, in line with previous reports. 21, 28 However, the chronotropic effect of epinephrine was 10% higher in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD animals ( Figure 1A and Table I in the online-only Data Supplement). Interestingly, epinephrine-treated PI3K␥ Ϫ/Ϫ mice displayed runs of premature ventricular beats, whereas no runs were observed in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD animals ( Figure 1B and 1C) . These data indicate that the kinaseindependent function of PI3K␥ regulates both the chronotropic and arrhythmogenic effects of myocardial ␤-AR stimulation.
PI3K␥ is a negative regulator of ␤ 2 -AR signaling. 29, 30 Furthermore, enhanced activation of cardiac ␤ 2 -ARs has been linked to the development of ventricular arrhythmias. 31, 32 Accordingly, pretreatment with the selective ␤ 2 -AR antagonist ICI-118551 (2 mg/kg IP) reduced the positive chronotropic effect of epinephrine ( Figure 1A ) and abolished the occurrence of ventricular runs in PI3K␥ Ϫ/Ϫ animals ( Figure  1B and 1C and Table I in the online-only Data Supplement). These data indicate that arrhythmias occurring in PI3K␥ Ϫ/Ϫ hearts are related to abnormal ␤ 2 -AR signaling. Next, to evaluate the role of PI3K␥-related arrhythmogenesis in heart failure, mice were subjected to transverse aortic constriction, a model characterized by the endogenous adrenergic stimulation of the myocardium. Of note, transverse aortic constriction caused substantially higher mortality in PI3K␥ Ϫ/Ϫ (59% on day 7) than in PI3K␥ ϩ/ϩ (8%) and PI3K␥ KD/KD (12%) mice (PϽ0.01; Figure 1D ). Serial ECG monitoring of transverse aortic constriction-treated animals revealed that PI3K␥ Ϫ/Ϫ mice developed sustained ventricular tachycardia immediately before death ( Figure 1E ).
Together, these data demonstrate that the scaffolding function of PI3K␥ protects against catecholamine-induced ventricular arrhythmia in both normal and failing hearts.
PI3K␥ Controls ␤ 2 -AR/cAMP Responses Through Compartmentalized PDE3 and PDE4
The relation between PI3K␥ and ␤ 2 -AR/cAMP signaling was evaluated in neonatal cardiomyocytes expressing the fluorescence resonance energy transfer sensor for intracellular cAMP, Epac2-cAMPs 22 (Figure 2A , insets). Activation of ␤ 2 -ARs by short application of isoproterenol (100 nmol/L, 15 seconds) combined with the ␤ 1 -AR antagonist CGP-20712A (100 nmol/L) produced a transient increase in cAMP that returned to baseline in Ͻ5 minutes (Figure 2A ). The decay of a cAMP response to a brief application of isoproterenol reflects the activity of cAMP PDEs. 24 As indicated by decay values, cAMP decay was 30% slower in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD cells ( Figure 2B ), demonstrating that cAMP hydrolysis by PDEs is impaired in the absence of PI3K␥.
In adult cardiomyocytes, cAMP generated by ␤ 2 -ARs is degraded by PDE3 and PDE4. 14, 15 A similar scenario was found in neonatal cells in which concomitant inhibition of PDE3 and PDE4 with Cilostamide (1 mol/L) and Ro-201724 (10 mol/L), respectively, almost completely blocked cAMP degradation (Figure IA-ID in the online-only Data Supplement). The selective contribution of PDE3 and PDE4 was then assessed. PDE3 inhibition by Cilostamide (1 mol/L) significantly slowed cAMP decay in all genotypes (Figure IIA-IIC and Table II in the online-only Data Supplement), indicating that PDE3 is required to limit ␤ 2 -AR-dependent cAMP. When PDE3 is blocked by Cilostamide, the decay of cAMP reflects the activity of PDE4. 24 The finding that cAMP decay was 2-fold slower in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD cardiomyocytes ( Figure 2C and 2D) indicated that PDE4 function is impaired in the absence of PI3K␥. Inhibition of PDE4 by Ro-201724 (10 mol/L) also significantly delayed cAMP decay (Figure  IIIA-IIIC and Table II in the online-only Data Supplement), demonstrating that PDE4 controls ␤ 2 -AR-dependent cAMP. When PDE4 is inhibited by Ro-201724, the rate of cAMP decay reveals the activity of PDE3. 24 In these conditions, cAMP degradation was 1.5-fold slower in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD cardiomyocytes ( Figure 2E and 2F), thus indicating that PDE3 fails to restore basal cAMP levels in cells lacking PI3K␥.
Because of the compartmentalization of cardiac PDEs, 33 PDE3 and PDE4 activities in the vicinity of ␤ 2 -ARs can differ from those in the bulk cytosol. Hence, subsarcolemmal ␤ 2 -AR/cAMP responses were analyzed in cardiomyocytes expressing pm-Epac2-cAMPs 23 Table III in the online-only Data Supplement), indicating that PDE3 does not control subsarcolemmal cAMP. In these conditions, cAMP decay reflects PDE4 activity. 24 Table III in the online-only Data Supplement) confirmed that PDE4 limits mainly subsarcolemmal cAMP. These data indicate that PI3K␥ controls PDE3 and PDE4 in distinct subcellular compartments.
To further prove a major involvement of PI3K␥ scaffold function, ␤ 2 -AR/cAMP responses were measured by a ICUE3 probe 34 in cardiomyocytes expressing a kinase-dead mutant PI3K␥ (PI3K␥KD-RFP; Figure VIIA Together, these data unveil a critical role for the scaffold function of PI3K␥ in terminating ␤ 2 -AR/cAMP signaling via compartmentalized modulation of PDE3 and PDE4. PI3K␥ Activates PDE4A, PDE4B, and PDE3A via PKA Different PDE3 and PDE4 isoenzymes are expressed in the myocardium. 13 The specific isoforms regulated by PI3K␥ were thus analyzed in adult whole hearts. The catalytic activity of PDE4A and PDE4B was 20% lower in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD heart membranes ( Figure 3A and 3B) but was unchanged in cytosolic fractions and total lysates ( Figure VIIIB in the online-only Data Supplement). Conversely, the activity of PDE4D, the other major myocardial PDE4 isoform, was independent of PI3K␥ ( Figure IXA in the onlineonly Data Supplement). In addition to PDE3B, 21 PDE3A activity was found to be 30% lower in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD heart membranes ( Figure 3C ) but not in cytosolic fractions and total lysates ( Figure VIIIC in the onlineonly Data Supplement). Thus, PI3K␥ regulates membranebound PDE4A, PDE4B, and PDE3A but not PDE4D.
The reduction of PDE activities detected in PI3K␥ Ϫ/Ϫ membranes was not linked to a decreased amount of PDE enzymes in this compartment ( Figure XA -XC in the onlineonly Data Supplement). Thus, PI3K␥ might promote PDE activation through a protein-protein interaction mechanism. Consistently, PI3K␥ copurified with the long 95-kDa isoform of PDE4A and with the long 92-kDa variant of PDE4B in adult hearts ( Figure 3D and 3E) . Two distinct PDE3A isoforms of 97 and 106 kDa also coprecipitated with PI3K␥ ( Figure 3F ). In line with cAMP PDE measurements, PI3K␥ was not found to interact with PDE4D ( Figure IXB in the online-only Data Supplement). These data indicate that PI3K␥ physically associates with and modulates PDE4A, PDE4B, and PDE3A but not PDE4D.
PI3K␥-associated PDE3B is activated by anchored PKA. 19 Because PKA also activates PDE3A 35 and long PDE4 iso-forms, 36 the ability of PI3K␥ to operate PKA-mediated activation of other PDEs was investigated. Of note, PDE4A, PDE4B, and PDE3A were part of macromolecular complexes containing PI3K␥ together with the regulatory and catalytic subunits of PKA ( Figure 4A-4C) . In isolated cardiomyocytes, the PKA inhibitor Myr-PKI (5 mol/L, 10 minutes) abolished the PI3K␥-dependent increase in PDE4A, PDE4B, and PDE3A activity ( Figure 4D-4F ). To further support the involvement of PKA, interaction studies in HEK293 cells expressing either a wild-type PI3K␥ (PI3K␥WT) or a mutant PI3K␥ that cannot bind PKA (PI3K␥K126A,R130A) 19 were performed. Transfected PI3K␥WT copurified with the long PDE4A variant endogenously expressed by HEK293 cells and increased PDE4A-mediated hydrolysis of cAMP by 30% ( Figure 5A ). On the contrary, PI3K␥K126A,R130A failed to enhance PDE4A activity while retaining the ability to copurify with the enzyme (Figure 5A) . Similarly, the catalytic activity of transfected PDE4B and PDE3A was significantly increased by the association with PI3K␥WT but not with PI3K␥K126A,R130A ( Figure 5B and 5C ). Thus, a loss of PKA anchoring prevents PI3K␥-dependent enhancement of PDE4A, PDE4B, and PDE3A activity.
Together, these data indicate that PI3K␥ is a multifunctional A-kinase anchoring protein that limits ␤ 2 -AR/cAMP responses via PKA-mediated activation of different PDEs.
cAMP-Mediated Phosphorylation of Ca v 1.2 and Phospholamban Is Increased in PI3K␥-Null Cardiomyocytes
The impact of PI3K␥ on cAMP-mediated signal transduction was evaluated next. In cardiomyocytes, cAMP-activated PKA modulates crucial effectors of excitation-contraction coupling such as LTCC, RyR, phospholamban, and troponin I. 4 PKA- mediated phosphorylation of the LTCC pore-forming subunit Ca v 1.2 was 3-fold higher in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ cardiomyocytes after ␤ 2 -AR activation ( Figure 6A ). Consistent with a major role of PI3K␥ in controlling sarcolemmal PDE4, Ca v 1.2 phosphorylation was significantly enhanced in PI3K␥ Ϫ/Ϫ over PI3K␥ ϩ/ϩ cardiomyocytes when the contribution of PDE4 was revealed by Cilostamide ( Figure  XI in the online-only Data Supplement). Moreover, PI3K␥ was found to be physically associated with Ca v 1.2 ( Figure   6B ), further supporting the view that PI3K␥ limits ␤ 2 -AR/cAMP signaling at the sarcolemma in proximity of the LTCC.
At the SR, PKA phosphorylates RyR and phospholamban. 4 Ser-2808 RyR phosphorylation was unchanged in PI3K␥ Ϫ/Ϫ compared with PI3K␥ ϩ/ϩ cardiomyocytes after ␤ 2 -AR stimulation ( Figure 6C ). On the contrary, Ser-16 phospholamban phosphorylation was 2.3-fold higher in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ cardiomyocytes ( Figure 6D ). In addition, phospholamban phosphorylation was significantly higher in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ cells when either PDE3 or PDE4 was inhibited by Cilostamide or Ro-201724 ( Figure  XIIA and XIIB in the online-only Data Supplement). These findings indicate that PI3K␥-activated PDE3 and PDE4 delimit ␤ 2 -AR/cAMP signaling at the SR in proximity of phospholamban but not of RyR. Similar to phospholamban, another intracellular target of PKA, troponin I, was hyperphosphorylated in PI3K␥ Ϫ/Ϫ cardiomyocytes on ␤ 2 -AR activation and when PDE3 and PDE4 were selectively blocked ( Figure XIIIA-XIIIC) .
Together, these data indicate that PI3K␥ affects key regulators of ventricular cardiomyocyte excitability by controlling local pools of ␤ 2 -AR/cAMP.
PI3K␥-Null Cardiomyocytes Develop Increased Spontaneous Ca 2؉ Release Events
cAMP-mediated phosphorylation of Ca v 1.2 and phospholamban enhances LTCC current amplitude and accelerates SR Ca 2ϩ reuptake, respectively. 4 Previous evidence demonstrated that PI3K␥ Ϫ/Ϫ adult cardiomyocytes have higher LTCC current density than PI3K␥ ϩ/ϩ cells after ␤ 2 -AR activation. 30 To explore the role of PI3K␥ in Ca 2ϩ homeostasis further, SR Ca 2ϩ release was analyzed in quiescent and epinephrine-treated adult cardiomyocytes ( Figure 7A ). Ca 2ϩ spark frequency was not significantly different between PI3K␥ ϩ/ϩ and PI3K␥ Ϫ/Ϫ cells after epinephrine ( Figure 7B ). In contrast, the effect of epinephrine on Ca 2ϩ spark occurrence was higher in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ cardiomyocytes ( Figure 7C) , revealing a hyperresponsiveness of PI3K␥ Ϫ/Ϫ cells to adrenergic stimulation. In addition, Ca 2ϩ spark amplitude was significantly increased in PI3K␥ Ϫ/Ϫ cardiomyocytes in basal conditions and further enhanced by adrenergic stimulation (Figure 7D) . Thus, spontaneous SR Ca 2ϩ release via RyR is enhanced in the absence of PI3K␥.
The impact of local Ca 2ϩ mishandlings on global intracellular Ca 2ϩ was evaluated next. Intracellular Ca 2ϩ transients were recorded in electrically paced (0.5 Hz) adult cardiomyocytes after application of epinephrine alone (100 nmol/L) or in combination with ICI-118551 (100 nmol/L). Spontaneous Ca 2ϩ release events were more frequent in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD cardiomyocytes ( Figure 8A-8C ). In line with in vivo experiments (Figure 1) , ICI-118551 abolished the occurrence of arrhythmic spontaneous Ca 2ϩ release events induced by epinephrine in PI3K␥ Ϫ/Ϫ cells ( Figure 8A-8C) . Thus, the scaffold function of PI3K␥ prevents spontaneous Ca 2ϩ release events after activation of ␤ 2 -ARs.
Together, these data demonstrate that PI3K␥ limits ␤ 2 -AR-dependent arrhythmogenic Ca 2ϩ release via PKAmediated activation of PDE4A, PDE4B, and PDE3A.
Discussion
The present study unravels a major role of PI3K␥ in the protection against catecholamine-induced ventricular arrhythmia. PI3K␥ Ϫ/Ϫ mice developed runs of premature ventricular contractions on ␤-AR stimulation caused by aberrant Ca 2ϩ release in ventricular cardiomyocytes. This proarrhythmic phenotype stems from a functional impairment in multiple cAMP PDEs, which leads to uncontrolled cAMP/PKA signaling. Our findings picture a scenario in which PI3K␥ orchestrates multiprotein complexes controlling both PKA-mediated activation of PDEs (PDE3A, PDE4A, PDE4B) and a physiological feedback inhibition of the Ca v 1.2 LTCC subunit and phospholamban.
The full rescue of ventricular arrhythmia with the ␤ 2 -AR antagonist ICI-118551 indicates a selective engagement of PI3K␥ downstream from the ␤ 2 -AR subtype. This finding is in agreement with the previous report of the increased cAMP accumulation detected in PI3K␥ Ϫ/Ϫ cardiomyocytes after stimulation with the ␤ 2 -AR agonist zinterol. 29 Furthermore, these results are consistent with evidence that the ␤ 2 -AR represents de facto the major ␤-AR isoform involved in arrhythmogenesis. 31, 32 Although our measurements excluded supraventricular arrhythmias, epinephrine-induced sinus tachycardia was more pronounced in PI3K␥ Ϫ/Ϫ than in PI3K␥ ϩ/ϩ and PI3K␥ KD/KD animals. This finding implies that PI3K␥ also influences sinoatrial node function in vivo and supports previous evidence that PI3K␥ increases spontaneous pacemaker activity in isolated sinoatrial node myocytes. 28 It has previously been reported that PI3K␥ directly associates with PKA and acts as an A-kinase anchoring protein involved in the negative regulation of cardiac cAMP. 19 The present study further demonstrates that PI3K␥ orchestrates the activity of multiple PDEs, including those with a major impact on cardiac function such as PDE4A, PDE4B, and PDE3A. This control is independent of PI3K␥ kinase activity and depends on protein scaffolding. Whether PI3K␥ regulates PDE3 or PDE4 has been a subject of debate. In whole hearts, PI3K␥ has been shown to regulate mainly PDE3B, independently of its kinase activity. 21 In contrast, in isolated cardiomyocytes, PI3K␥ appears to modulate PDE4 but not PDE3 activity. 18 The present study provides a solution to this controversy in that PI3K␥ was found to cooperate with either PDE3 or PDE4, depending on the subcellular compartment. Fluorescence resonance energy transfer-based assays demonstrated that the main PDE activated by PI3K␥ in the cytosol is PDE3. Conversely, PI3K␥ controls PDE4-but not PDE3-dependent cAMP pools close to the plasma membrane.
The finding that PDE3 is not required for the modulation of ␤ 2 -AR/cAMP signaling at the plasma membrane was unexpected because PDE3 isoenzymes are known to be membrane bound. [37] [38] [39] However, PDE3 localizes mainly at the SR/ endoplasmic reticulum rather than at the plasma membrane. 38 In agreement with this idea, PDE3A was modulated by PI3K␥ in total heart membranes, which contain also SR/ endoplasmic reticulum membranes, but not at the plasma membrane, as detected by the pm-Epac2-cAMPs sensor. On the other hand, the major role of PDE4 in controlling sarcolemmal cAMP is supported by previous evidence that both PDE4A and PDE4B can localize to this compartment. 16, 40, 41 Our findings demonstrate that the activity of these pools of PDE4A and PDE4B relies on PI3K␥ scaffold activity. Taken together, present and previous data indicate that PI3K␥ regulates the coincident signaling of PDE3 and PDE4 by acting in spatially confined compartments of cardiomyocytes.
PI3K␥-dependent tuning of multiple PDEs is required to limit PKA-mediated activation of the excitation-contraction coupling machinery, including the sarcolemmal LTCC and phospholamban at the SR. The present work demonstrates that PI3K␥ operates a feedback loop inhibiting PKAmediated phosphorylation of the Ca v 1.2 subunit of LTCC on ␤-AR stimulation. This mechanism eventually explains the previous report of increased LTCC current density (I Ca,L ) in PI3K␥ Ϫ/Ϫ cardiomyocytes 30 and the present finding that PI3K␥ Ϫ/Ϫ mice develop calcium-dependent arrhythmia. Similarly, enhanced activation of LTCC is the main trigger of ventricular tachycardia detected in PDE4B Ϫ/Ϫ mice. 16 The proarrhythmic effect of uncontrolled LTCC function has also been shown in humans, in whom a missense mutation of Ca v 1.2 causing increased channel opening leads to severe arrhythmias. 42 PDE4B is part of the Ca v 1.2 channel complex and acts as a negative regulator of I Ca,L under ␤-AR stimulation. 16 The finding that PI3K␥ associates with Ca v 1.2 suggests that PI3K␥-mediated control of PDE4B activity in the Ca v 1.2 channel complex is another mechanism by which PI3K␥ confers protection against cardiac arrhythmia.
The effects of enhanced I Ca,L detected in PI3K␥ Ϫ/Ϫ cardiomyocytes can be further strengthened by increased diastolic Ca 2ϩ release caused by more intense Ca 2ϩ sparks. This effect can be indirectly linked to enhanced Ca 2ϩ entry through hyperphosphorylated LTCC and to hyperphosphorylation of phospholamban, which in turn stimulates Ca 2ϩ reuptake, increasing SR Ca 2ϩ load. On the contrary, PKAmediated phosphorylation of RyR did not require PI3K␥, and Ca 2ϩ spark frequency was thus maintained in PI3K␥ Ϫ/Ϫ cardiomyocytes. This is consistent with previous evidence that RyR activity is PI3K␥ independent 18 but relies on the regulation of a complex containing PDE4D. 2 Accordingly, PI3K␥ neither associated with nor controlled the catalytic activity of PDE4D.
Conclusions
This study identifies PI3K␥ as a central switch of cAMP compartmentalization that affects multiple ␤ 2 -AR/cAMP microdomains via localized PKA-mediated activation of distinct PDEs. Such spatiotemporal organization of cAMP signaling allows the physiological regulation of cardiac function, translating ␤ 2 -AR stimulation into the appropriate cardiac response. This mechanism appears relevant to heart failure, in which ventricular arrhythmia is a major cause of death. Interestingly, failing hearts show a functional decay in PI3K␥-directed protein complexes. 19 Hence, deregulation of PI3K␥ scaffold function may constitute an important component of heart failure-related arrhythmias.
